Landos Biopharma Inc
NASDAQ:LABP
Landos Biopharma Inc
NASDAQ:LABP
Price:
22.93 USD
0.58%
Market Closed
Updated:
May 29, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of LABP.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
LABP
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
LABP Competitors Multiples
Landos Biopharma Inc Competitors
Landos Biopharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Landos Biopharma Inc
NASDAQ:LABP
|
71.5m USD | 0 | -2.9 | -1.7 | -1.7 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
767.8B USD | 21.4 | 125.1 | 61.2 | 69.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.7 | 45.7 | 34.1 | 37.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
347.5B USD | 4.1 | 9 | 11.1 | 14.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
319.3B USD | 5.2 | 138.5 | 34.6 | 56.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.5B GBP | 5 | 37.6 | 174.5 | 278.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
182.4B CHF | 3.1 | 15.9 | 9 | 10.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
178.3B CHF | 3.3 | 11.1 | 8.5 | 12.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
160.4B USD | 2.9 | -519 | 12.6 | 20.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
